source
- STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head studyEli Lilly announced that its investigational drug retatrutide was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic in a large diabetes study.STAT · 13d ago↗ source
- Lilly’s retatrutide trounces Novo’s Ozempic in diabetes, weight lossEli Lilly’s next-gen weight loss drug retatrutide soundly beat Novo’s approved medicine Ozempic in weight loss and blood sugar reduction, padding the case for a regulatory application that’s expect…BioSpace · 13d ago↗ source
- Phase 3 trial shows cancer vaccine intismeran autogene cuts recurrence risk by 42% versus KeytrudaAt the European Society for Medical Oncology Congress, a Phase 3 trial of the personalized cancer vaccine intismeran autogene reported a 42% reduction in risk of recurrence or death compared with p…